Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook
Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report
In July 2025, Prescient Therapeutics Ltd. announced a phase 2 study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL).
In July 2025, Dren Bio conducted a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas.
In July 2025, Soligenix announced a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible light.The study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
DelveInsight's Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment.
The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment
Cutaneous T-cell lymphoma Emerging Drugs
HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States.
AFM13: Affimed GmbH
AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma.
ASTX660: Otsuka Pharmaceutical Co., Ltd
ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL.
WUCART007: Wugen
WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL.
The Cutaneous T-Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.
Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.
Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs
Cutaneous T-Cell Lymphoma Companies
HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Cutaneous T-Cell Lymphoma Pipeline Report
Coverage- Global
Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
Cutaneous T-cell lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cutaneous T-cell lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
AFM13: Affimed GmbH
Early Stage Products (Phase I)
WUCART007: Wugen
Preclinical Stage Products
Drug Name: Company Name
Inactive Products
Cutaneous T-cell lymphoma Key Companies
Cutaneous T-cell lymphoma Key Products
Cutaneous T-cell lymphoma- Unmet Needs
Cutaneous T-cell lymphoma- Market Drivers and Barriers
Cutaneous T-cell lymphoma- Future Perspectives and Conclusion
Cutaneous T-cell lymphoma Analyst Views
Cutaneous T-cell lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
Why Prime Video Is One of Amazon's Most Underrated Assets
Key Points Prime Video is no longer a cost center. Prime Video has more than 200 million viewers. Commerce, content, and ads are converging for Amazon. 10 stocks we like better than Amazon › Amazon(NASDAQ: AMZN) is best known for its sprawling e-commerce empire, dominant cloud infrastructure business, and its ever-growing Prime membership base. But quietly sitting inside this flywheel is a business with surprising strategic upside: Prime Video. For years, Prime Video was viewed as just another perk -- a nice-to-have feature bundled into the Prime membership. But that's changing. Between a new ad-supported model, a powerful position in connected TV (CTV), and seamless integration into Amazon's broader retail ecosystem, Prime Video is emerging as one of Amazon's most underrated growth engines. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Here's why smart investors should start paying closer attention. Prime Video's strategic shift from perks to platform When Amazon first launched Prime Video, it wasn't trying to compete directly with entertainment companies like Netflix or Disney. Instead, it used video content to increase Prime subscriptions, drive loyalty, and reduce churn. The focus was to delight its e-commerce customers, and that strategy worked. Happy customers became more engaged, spending more time and money on the e-commerce platform. But what started as a defensive move has become a strategic pillar. Today, in addition to getting free content as Prime members, customers can also subscribe to third-party channels offered by partners under the Amazon Channel. Besides, Amazon made another pivotal move in January 2024: it began running ads on Prime Video, instantly unlocking a massive audience of over 200 million globally to advertisers. The streaming arm is also increasingly investing in originals, live sports, and localized content across global markets. In other words, Prime Video is quietly building up its ecosystem of services, positioning it well to evolve from a cost-center to a hugely profitable entity of its own. Amazon Ads and Prime Video Amazon Ads is one of the next growth frontiers for Amazon, in which Prime Video is going to play a major role. By rolling out ads across Prime Video by default in key markets, Amazon steps up its monetization efforts of its gigantic Prime subscriber base. Prime members can pay a small monthly fee to go ad-free, but most don't, turning Prime Video into one of the largest ad-supported streaming platforms globally. To put the opportunity size into perspective, Netflix has 300 million subscribers, of which 94 million use the ad-supported service. On the other hand, Disney+ has 126 million global paid subscribers. With more than 200 million viewers, Prime Video is already among the biggest streaming services provided globally. But Prime Video doesn't run an ordinary advertising business. Its ad engine taps into its vast retail data, letting brands target viewers based on actual purchase behavior. A viewer watching an online video might see a relevant sponsored product ad and buy it on Amazon without ever leaving the app. It's a frictionless loop that few competitors can replicate. Owning the connected TV stack Prime Video isn't just a content platform -- it's Amazon's gateway to the living room. And through its connected TV (CTV) footprint, Amazon is building an end-to-end advertising and commerce engine few can match. Amazon Fire TV, now with over 200 million devices sold globally, gives the company direct control over the connected TV hardware and software stack. This integrated approach allows it to collect first-party data, control the user experience, and serve ads more effectively than most CTV players. While traditional media networks are still figuring out how to merge streaming, commerce, and advertising, Amazon already has all three pieces in place. The implications are enormous. Advertisers not only reach an engaged, high-intent audience on Prime Video, but they can also close the loop through Amazon's retail engine. That kind of direct attribution -- seeing a sponsored ad on Fire TV, clicking through, and buying the product on Amazon -- is a marketer's dream. With increasing demand for measurable, performance-based advertising, this positions Amazon as a formidable player in the future of CTV. In other words, Prime Video plays a strategic role in Amazon's expanding ecosystem, in which commerce, content, and advertising converge to form a defensible business model that strengthens both the parts and the whole. Now is the time to take a closer look at Prime Video Investors often think of Amazon in silos: retail, cloud, advertising, logistics, etc. But the company's greatest strength lies in how these pieces connect. Prime Video may have started as a "nice-to-have" feature bundled into Prime, but it's quickly becoming one of Amazon's most powerful strategic assets. By bringing together entertainment, commerce, and advertising into a seamless flywheel, Amazon is building a future where Prime Video not only entertains--but drives growth across the entire business. It's time investors gave this overlooked asset a much closer look. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Netflix, and Walt Disney. The Motley Fool has a disclosure policy.
Globe and Mail
30 minutes ago
- Globe and Mail
Why Everyone Is Talking About Sirius XM Stock
Key Points Sirius XM generates recurring subscription revenue. Berkshire Hathaway owns over one-third of the company. However, Sirius XM faces challenges in expanding its reach. 10 stocks we like better than Sirius XM › Sirius XM (NASDAQ: SIRI) isn't often the center of attention, unlike some of its larger media peers, such as Netflix or Spotify. But that's starting to change. The stock has dropped more than 40% from its highs (as of this writing) in the last 12 months, drawing interest from value hunters and long-term investors alike. And beneath the surface, there's more to the story than meets the eye. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » So why is everyone talking about Sirius XM stock right now? Here's what investors need to know. Sirius XM operates a recurring revenue business model Sirius XM operates a subscription-based satellite and streaming audio service. Its core business revolves around delivering a broad range of audio content, including music, sports, news, talk shows, and entertainment, to users across North America. For a monthly fee -- depending on the plan -- subscribers gain access via factory-installed satellite radios in vehicles, the SiriusXM app, and smart speakers or other connected devices. Subscription revenue accounts for 76% of the company's total, making it the cornerstone of the business. Sirius XM also generates revenue from advertising (20% of revenue), mainly from users who subscribe to the ad - supported content, primarily through Pandora and podcasting. The remaining 4% of revenue comes from licensing and other hardware sales. In other words, Sirius XM is effectively a hybrid between legacy media and digital streaming, built around vehicle-based installations and habitual listening patterns. Sirius XM has huge backing from smart investors One reason the stock is making headlines is that Berkshire Hathaway owns 35.4% of Sirius XM -- a sizable bet, and not a recent one. Warren Buffett's team has been accumulating shares for years, suggesting long-term conviction. While we can only speculate why Berkshire Hathaway has purchased such a massive stake in the company, there are at least two likely reasons. First, Sirius XM's subscription business is sticky and recurring, with a loyal base of drivers who regularly tune in -- a strong foundation for cash generation, even amid modest subscriber losses. And that brings us to the second point, which is Sirius XM's disciplined capital allocation framework. Historically, the media company has shown restraint in deploying excess capital, focusing on returning cash to shareholders through buybacks and dividends rather than on flashy acquisitions. In the last five years alone, it has repurchased $4 billion worth of stocks. This mix of reliable cash flow and conservative capital use aligns well with Berkshire's investing philosophy. A cheap stock, but not without risk Sirius XM's recent poor stock performance has led to its attractive valuation. As of the time of writing, it has a price-to-sales (P/S) ratio of 1, down from its five-year high of 3. Comparatively, Spotify trades at a P/S ratio of 8.3 times. The stock looks cheap, but there are real challenges: Sirius XM posted a net loss in 2024, a reversal from its history of profitability. While the loss was primarily due to one-time restructuring and impairment charges, it suggests that the company faces some challenges going forward. Revenue has declined from $9 billion in 2022 to $8.7 billion in 2024, signaling saturation in its core market. Paid subscribers are slipping -- down from 34.9 million in 2019 to 33.2 million in 2024. While Sirius XM remains highly profitable on the cash flow level, having generated $1 billion in free cash flow in 2024, its declining revenue suggests that it is struggling to compete against younger peers like Spotify in expanding its reach. Sirius XM is pinning hopes on its advertising and podcast business, including its acquisition of Pandora. But that turnaround remains a work in progress. Pandora remains far behind the category leaders, and competition in podcasting is fierce. Worse still, Panda's monthly active users have been declining over the last five years as well, down from 63.5 million to 43.3 million. In other words, while Sirius XM still has a loyal base of subscribers, this cohort is contracting over the years, with no sign of a turnaround anytime soon. What does it all mean? Sirius XM is a paradox: It's not growing, but it's still throwing off tons of cash. And while its audio subscription business model looks dated, it has the backing of one of the most respected investors of our time. Whether Sirius is a value trap or a misunderstood opportunity depends on investors' perspective. The company faces real risks, but if it can stabilize its subscriber base and revitalize Pandora, there could be meaningful upside from here. Either way, it's one worth keeping on your radar. Should you invest $1,000 in Sirius XM right now? Before you buy stock in Sirius XM, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sirius XM wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
42 minutes ago
- Globe and Mail
ExxonMobil Reports Strong Q2 2025 Earnings Amid Market Challenges
Exxon Mobil Corp. ( (XOM) ) has released its Q2 earnings. Here is a breakdown of the information Exxon Mobil Corp. presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Exxon Mobil Corporation, a leading oil and gas company, operates in the energy sector, focusing on the exploration, production, and distribution of petroleum and petrochemical products globally. In its second-quarter 2025 earnings report, ExxonMobil reported earnings of $7.1 billion, with a cash flow from operations of $11.5 billion, highlighting its strong financial performance despite challenging market conditions. The company also returned $9.2 billion to shareholders, continuing its commitment to shareholder value. Key financial metrics included a decrease in year-to-date earnings to $14.8 billion from $17.5 billion in the first half of 2024, attributed to weaker crude prices and refining margins. However, the company achieved significant structural cost savings of $1.4 billion and increased production in the Permian and Guyana regions. ExxonMobil also commenced operations at several key projects, enhancing its portfolio of high-value products. The company maintained a strong balance sheet with industry-leading debt ratios and declared a third-quarter dividend of $0.99 per share. Cash capital expenditures were reported at $12.3 billion year-to-date, aligning with its full-year guidance. Looking ahead, ExxonMobil remains focused on executing its strategic projects and cost-saving initiatives, positioning itself for continued growth and profitability in the evolving energy landscape. Disclaimer & DisclosureReport an Issue
